ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Acupressure reduced fatigue in breast cancer survivors

Omega-3 fatty acid stops known trigger of lupus

What’s Fenugreek Good For?

Print Page
Email Article

Drug Reduces Signs and Symptoms of Rheumatoid Arthritis

  [ 1 vote ]   [ Discuss This Article ]
By News release • • January 5, 2000

ABSTRACT: BOSTON, MA, November 15, 1999 -- Alexion Pharmaceuticals, Inc. reported yesterday that rheumatoid arthritis patients receiving a single dose of its anti-inflammatory complement inhibitor 5G1.1 showed a significant reduction in the signs and symptoms of the often painful joint condition as compared to placebo-treated patients.

The completed clinical trial examined the safety and biologic activity of 5G1.1 in 42 patients with mild to moderate rheumatoid arthritis, each of whom received a single dose of the drug. The company presented data at the 63rd annual American College of Rheumatology (ACR) meeting demonstrating that 50% of the patients (n=6) who received a single 8 mg/kg dose achieved an ACR20 score, as compared to 10% of the patients (n=10) treated with placebo (P=.07). ACR20 score means that a patient had a 20% improvement in tender and swollen joint count plus 20% improvement in at least 3 of 5 of the following criteria: patient pain assessment, physician global assessment, patient global assessment, patient self-assessed disability and acute phase reactant. It was previously reported in April 1999 that the single 8 mg/kg dose resulted in a 30% decrease (P<.05) in the levels of the acute phase reactant C-reactive protein, an objective measure of disease activity.

"The study's results demonstrate that rheumatoid arthritis patients who received a single dose of Alexion's anti-inflammatory C5 Complement Inhibitor drug, 5G1.1, felt less pain and were better able to function than those patients receiving placebo," said Dr. Leonard Bell, President and Chief Executive Officer of Alexion. "Further, the clinical measurement in the current study, ACR20 score, which is the same endpoint of our ongoing Phase II safety and efficacy trial with 5G1.1, was met."

The report, entitled "A Single Dose, Placebo Controlled, Double Blind, Phase I Study of the Humanized Anti-C5 Antibody h5G1.1 in Patients with Rheumatoid Arthritis," is based on a clinical trial conducted by investigators at North Shore Hospital, Gainesville Clinical Research Center and University of Alabama in collaboration with Alexion. Dr. Christopher Mojcik, a clinical rheumatologist and Senior Director of Clinical Development at Alexion, presented the clinical data.

"In follow-up to this initial single dose 5G1.1 trial in rheumatoid arthritis patients, we are currently enrolling up to 200 patients in a Phase II efficacy trial employing multiple doses of 5G1.1 in rheumatoid arthritis patients," commented Dr. Mojcik. "We are examining the safety and efficacy of multiple doses of 5G1.1 with the primary efficacy endpoint as the ACR20 score."
It is estimated that more than two million patients are affected by rheumatoid arthritis, a disease in which the immune system attacks multiple joints as well as the whole body. This chronic immune attack frequently involves multiple organs in the body leading to the onset of fatigue, severe joint destruction, pain and disfigurement.

Dr. Jacques Caldwell of Gainesville Clinical Research Center, a principal investigator in the completed trial and ongoing Phase II trial, commented, "In my experience, inhibition of the complement pathway is a unique approach to treating rheumatoid arthritis. Hopefully, these early results will be confirmed by the ongoing studies in a larger patient cohort."

Alexion's C5 complement inhibitors are designed to selectively block the production of inflammation-causing proteins in a process of the human immune system as the complement cascade. Alexion believes that selective suppression of this immune response will provide a significant therapeutic advantage relative to existing therapies. Because of the generally beneficial effects of the components of the complement cascade prior to C5 and the greater inflammatory disease-promoting effects of the cleavage products of C5, the Company has identified C5 as a potentially effective anti-inflammatory drug target. The first two C5 Inhibitors, 5G1.1 and 5G1.1-SC, specifically and tightly bind to C5 blocking its cleavage into harmful byproducts and are designed to inhibit subsequent damage from the inflammatory process. 5G1.1 is currently being tested in Phase II safety and efficacy trials in rheumatoid arthritis and membranous nephritis patients.

Source: Alexion Pharmaceuticals

Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg FibroSleep™ Optimized Curcumin Longvida®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Priming Your Immune System for Cold & Flu Season Priming Your Immune System for Cold & Flu Season
Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7
Coconut Oil - Healthy Gifts from the 'Tree of Life' Coconut Oil - Healthy Gifts from the 'Tree of Life'
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
Physically and Mentally Exhausted? How to Restore Energy at Its Source Physically and Mentally Exhausted? How to Restore Energy at Its Source

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map